In a multicenter, randomized, double-blind, placebo-controlled, parallel group trial, budesonide oral suspension improved symptomatic, endoscopic, and histologic outcomes in patients with symptomatic eosinophilic esophagitis.
This entry was posted in News. Bookmark the permalink.